Try our Advanced Search for more refined results
Par Pharmaceutical, Inc. v. Novartis AG
Case Number:
Case Type:
IPR
Status:
Final Written Decision
Petitioner:
Par Pharmaceutical, Inc.
Patent Owner:
Novartis AG
Tech Center:
1600
-
Filed: July 22, 2016 00:00
Coverage
-
February 21, 2017
Par Gets PTAB Review Of Afinitor Patent
Days after rejecting a challenge from Roxane Laboratories to a patent related to Novartis' blockbuster cancer drug Afinitor, the Patent Trial and Appeal Board agreed recently to review the patent based on a challenge from another generic drugmaker, Par Pharmaceutical.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Search PTAB cases and full-text documents.
- Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
- Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
View the PTAB case documentsAlready a subscriber? Click here to login
-
February 21, 2017